Efficacy of Suxiao Jiuxin Pill on Coronary Heart Disease: A Meta-Analysis of Randomized Controlled Trials

被引:19
|
作者
Ren, Li [1 ]
Wang, Jie [1 ]
Feng, Ling [1 ]
Wang, Shuli [1 ]
Li, Jun [1 ]
机构
[1] China Acad Chinese Med Sci, Guanganmen Hosp, Dept Cardiovasc, Beijing 100053, Peoples R China
关键词
ATRIAL-FIBRILLATION; LIGUSTICUM-CHUANXIONG; PREVALENCE;
D O I
10.1155/2018/9745804
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Suxiao jiuxin pill is considered an effective ancillary drug in patients with coronary heart disease. Although numerous small, single-center clinical trials have been conducted, the benefits and harms of suxiao jiuxin pill remain controversial. We performed a meta-analysis to clarify the efficacy of suxiao jiuxin pill on patients with coronary heart disease. Randomized controlled trials were identified by using the Cochrane Library, PubMed, Web of Science, Embase, Wanfang, Weipu, and China Knowledge Resource Integrated databases (until June 2016). Pooled relative risks (RR), weighted mean differences (WMD), and 95% confidence intervals (95% CIs) were estimated using random-effects models. Forty-one trials involving 6276 patients were included in our analysis. Administration of suxiao jiuxin pill significantly improved electrocardiogram (ECG) results when compared with other therapies (RR 1.32, 95% CI 1.26 to 1.38, and P < 0.001). Subgroup analyses revealed that suxiao jiuxin pills improve ECG results more than salvia tablets (RR 1.54, 95% CI 1.41 to 1.67, and P < 0.001), isosorbide dinitrate (RR 1.14, 95% CI 1.21 to 1.44, and P = 0.001), nitroglycerin (RR 1.35, 95% CI 1.16 to 1.56, and P < 0.001), and other drugs (RR 1.32, 95% CI 1.21 to 1.44, and P < 0.001). Available evidence additionally suggests that suxiao jiuxin pills could significantly reduce total cholesterol (WMD -0.62 mmol/L, 95% CI -1.06 to -0.18 mmol/L, and P = 0.005) and low-density lipoprotein (LDL) levels (WMD -1.12 mmol/L, 95% CI -1.42 to -0.82 mmol/L, and P < 0.001) and increase high-density lipoprotein (HDL) levels (WMD 0.32 mmol/L, 95% CI 0.07 to 0.58 mmol/L, and P = 0.014). However, no significant differences were observed in total triglyceride levels, plasma viscosity, hematocrit, and fibrinogen. No incidences of adverse reactions were observed after administration of suxiao jiuxin pill. Improvements in ECG results and lipid profiles were also observed after suxiao jiuxin administration compared to other therapies. It also decreased low-cut and high-cut whole blood viscosity without significant adverse reactions.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Comment on "Efficacy and safety of colchicine in patients with coronary artery disease: A systematic review and meta-analysis of randomized controlled trials"
    Liang, Huiying
    Huang, Donghua
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (06) : 3000 - 3001
  • [42] Coronary revascularization for heart failure with coronary artery disease: A systematic review and meta-analysis of randomized trials
    Iaconelli, Antonio
    Pellicori, Pierpaolo
    Dolce, Pasquale
    Busti, Matteo
    Ruggio, Aureliano
    Aspromonte, Nadia
    D'Amario, Domenico
    Galli, Mattia
    Princi, Giuseppe
    Caiazzo, Elisabetta
    Rezig, Asma O. M.
    Maffia, Pasquale
    Pecorini, Giovanni
    Crea, Filippo
    Cleland, John G. F.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 (07) : 1094 - 1104
  • [43] The efficacy of mindfulness-based intervention for heart diseases: A meta-analysis of randomized controlled trials
    Kang, Qingxia
    Luo, Aihua
    MEDICINE, 2022, 101 (39) : E29649
  • [44] Safety and Efficacy of Istaroxime in Patients With Acute Heart Failure: A Meta-Analysis of Randomized Controlled Trials
    Khan, Saad Khalid
    Rawat, Anurag
    Khan, Zarghuna
    Reyaz, Ibrahim
    Kumar, Vikash
    Batool, Saima
    Yadav, Rambabu
    Hirani, Shamsha
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (06)
  • [45] Efficacy of catheter ablation for atrial fibrillation in heart failure: a meta-analysis of randomized controlled trials
    Zhang, Zhongyin
    Zheng, Yan
    He, Wenxiu
    Wei, Jiahe
    Li, Pengzhan
    Zhong, Guoqiang
    Jiang, Zhiyuan
    ESC HEART FAILURE, 2024,
  • [46] Efficacy and safety of sacubitril-valsartan in heart failure: a meta-analysis of randomized controlled trials
    Zhang, Hongzhou
    Huang, Tieqiu
    Shen, Wen
    Xu, Xiuxiu
    Yang, Pingping
    Zhu, Dan
    Fang, Haiyang
    Wan, Hongbing
    Wu, Tao
    Wu, Yanqing
    Wu, Qinghua
    ESC HEART FAILURE, 2020, 7 (06): : 3841 - 3850
  • [47] Exercise-based rehabilitation for patients with coronary heart disease: Systematic review and meta-analysis of randomized controlled trials
    Taylor, RS
    Brown, A
    Ebrahim, S
    Jolliffe, J
    Noorani, H
    Rees, K
    Skidmore, B
    Stone, JA
    Thompson, DR
    Oldridge, N
    AMERICAN JOURNAL OF MEDICINE, 2004, 116 (10): : 682 - 692
  • [48] Adjuvant Treatment with Qilin Pill for Men with Oligoasthenospermia: A Meta-Analysis of Randomized Controlled Trials
    Jin, Xin
    Man, Changfeng
    Gong, Dandan
    Fan, Yu
    PHYTOTHERAPY RESEARCH, 2017, 31 (09) : 1291 - 1297
  • [49] Comparative Efficacy of Chinese Herbal Injections for Pulmonary Heart Disease: A Bayesian Network Meta-Analysis of Randomized Controlled Trials
    Wang, Kaihuan
    Wu, Jiarui
    Wang, Haojia
    Duan, Xiaojiao
    Zhang, Dan
    Wang, Yingzi
    Ni, Mengwei
    Liu, Shuyu
    Meng, Ziqi
    Zeng, Xiantao
    Zhang, Xiaomeng
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [50] Comparative efficacy on outcomes of C-CABG, OPCAB, and ONBEAT in coronary heart disease: a systematic review and network meta-analysis of randomized controlled trials
    Zhu, Lin
    Li, Dongjie
    Zhang, Xu
    Wan, Sitong
    Liu, Yuyong
    Zhang, Hongjia
    Luo, Junjie
    Luo, Yongting
    An, Peng
    Jiang, Wenjian
    INTERNATIONAL JOURNAL OF SURGERY, 2023, 109 (12) : 4263 - 4272